BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 16189015)

  • 1. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge.
    Yang G; Pevear DC; Davies MH; Collett MS; Bailey T; Rippen S; Barone L; Burns C; Rhodes G; Tohan S; Huggins JW; Baker RO; Buller RL; Touchette E; Waller K; Schriewer J; Neyts J; DeClercq E; Jones K; Hruby D; Jordan R
    J Virol; 2005 Oct; 79(20):13139-49. PubMed ID: 16189015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures.
    Duraffour S; Snoeck R; de Vos R; van Den Oord JJ; Crance JM; Garin D; Hruby DE; Jordan R; De Clercq E; Andrei G
    Antivir Ther; 2007; 12(8):1205-16. PubMed ID: 18240860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific targeting of the F13L protein by ST-246 affects orthopoxvirus production differently.
    Duraffour S; Vigne S; Vermeire K; Garcel A; Vanstreels E; Daelemans D; Yang G; Jordan R; Hruby DE; Crance JM; Garin D; Andrei G; Snoeck R
    Antivir Ther; 2008; 13(8):977-90. PubMed ID: 19195323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ST-246 is a key antiviral to inhibit the viral F13L phospholipase, one of the essential proteins for orthopoxvirus wrapping.
    Duraffour S; Lorenzo MM; Zöller G; Topalis D; Grosenbach D; Hruby DE; Andrei G; Blasco R; Meyer H; Snoeck R
    J Antimicrob Chemother; 2015 May; 70(5):1367-80. PubMed ID: 25630650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased susceptibility of Cantagalo virus to the antiviral effect of ST-246®.
    Santos-Fernandes É; Beltrame CO; Byrd CM; Cardwell KB; Schnellrath LC; Medaglia ML; Hruby DE; Jordan R; Damaso CR
    Antiviral Res; 2013 Mar; 97(3):301-11. PubMed ID: 23257396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response.
    Paran N; Lustig S; Zvi A; Erez N; Israely T; Melamed S; Politi B; Ben-Nathan D; Schneider P; Lachmi B; Israeli O; Stein D; Levin R; Olshevsky U
    Virol J; 2013 Jul; 10():229. PubMed ID: 23842430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.
    Kern ER; Prichard MN; Quenelle DC; Keith KA; Tiwari KN; Maddry JA; Secrist JA
    Antimicrob Agents Chemother; 2009 Feb; 53(2):572-9. PubMed ID: 19029322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
    Quenelle DC; Buller RM; Parker S; Keith KA; Hruby DE; Jordan R; Kern ER
    Antimicrob Agents Chemother; 2007 Feb; 51(2):689-95. PubMed ID: 17116683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary Screening and In Vitro Confirmation of Orthopoxvirus Antivirals.
    Grosenbach DW; Hruby DE
    Methods Mol Biol; 2019; 2023():143-155. PubMed ID: 31240676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
    Quenelle DC; Prichard MN; Keith KA; Hruby DE; Jordan R; Painter GR; Robertson A; Kern ER
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4118-24. PubMed ID: 17724153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
    Berhanu A; King DS; Mosier S; Jordan R; Jones KF; Hruby DE; Grosenbach DW
    Antimicrob Agents Chemother; 2009 Dec; 53(12):4999-5009. PubMed ID: 19752270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses.
    Smee DF; Sidwell RW; Kefauver D; Bray M; Huggins JW
    Antimicrob Agents Chemother; 2002 May; 46(5):1329-35. PubMed ID: 11959564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A human recombinant analogue to plasma-derived vaccinia immunoglobulin prophylactically and therapeutically protects against lethal orthopoxvirus challenge.
    Parker S; D'Angelo J; Buller RM; Smee DF; Lantto J; Nielsen H; Jensen A; Prichard M; George SL
    Antiviral Res; 2021 Nov; 195():105179. PubMed ID: 34530009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice.
    Grosenbach DW; Berhanu A; King DS; Mosier S; Jones KF; Jordan RA; Bolken TC; Hruby DE
    Proc Natl Acad Sci U S A; 2010 Jan; 107(2):838-43. PubMed ID: 20080762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (+)-Camphor and (-)-borneol derivatives as potential anti-orthopoxvirus agents.
    Sokolova AS; Kovaleva KS; Yarovaya OI; Bormotov NI; Shishkina LN; Serova OA; Sergeev AA; Agafonov AP; Maksuytov RA; Salakhutdinov NF
    Arch Pharm (Weinheim); 2021 Jun; 354(6):e2100038. PubMed ID: 33605479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in the discovery of compounds inhibiting orthopoxviruses in animal models.
    Smee DF
    Antivir Chem Chemother; 2008; 19(3):115-24. PubMed ID: 19024628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell line dependency for antiviral activity and in vivo efficacy of N-methanocarbathymidine against orthopoxvirus infections in mice.
    Smee DF; Wandersee MK; Bailey KW; Wong MH; Chu CK; Gadthula S; Sidwell RW
    Antiviral Res; 2007 Jan; 73(1):69-77. PubMed ID: 16712967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of lethal cowpox virus respiratory infections in mice with 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine and its orally active diacetate ester prodrug.
    Smee DF; Bailey KW; Sidwell RW
    Antiviral Res; 2002 May; 54(2):113-20. PubMed ID: 12062396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host.
    Fang M; Cheng H; Dai Z; Bu Z; Sigal LJ
    Virology; 2006 Feb; 345(1):231-43. PubMed ID: 16256161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mouse models for studying orthopoxvirus respiratory infections.
    Schriewer J; Buller RM; Owens G
    Methods Mol Biol; 2004; 269():289-308. PubMed ID: 15114022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.